Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo- Controlled Trial Dipankar Sircar, MD, DM, Soumya Chatterjee, MD, Rajesh Waikhom, MD, DM, Vishal Golay, MD, DM, Arpita Raychaudhury, MD, DM, Suparna Chatterjee, MD, Rajendra Pandey, MD, DM American Journal of Kidney Diseases Volume 66, Issue 6, Pages 945-950 (December 2015) DOI: 10.1053/j.ajkd.2015.05.017 Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions
Figure 1 Flow diagram of single-center trial evaluating febuxostat in comparison to placebo in asymptomatic hyperuricemia in individuals with chronic kidney disease stages 3 to 4. American Journal of Kidney Diseases 2015 66, 945-950DOI: (10.1053/j.ajkd.2015.05.017) Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions